DelveInsight’s, “Autoimmune Hepatitis Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Autoimmune Hepatitis pipeline landscape. It covers the Autoimmune Hepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autoimmune Hepatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Autoimmune Hepatitis Pipeline Report

• DelveInsight’s Autoimmune Hepatitis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Autoimmune Hepatitis treatment.
• The leading companies working in the Autoimmune Hepatitis Market include Novartis, TaiwanJ Pharmaceuticals Co., Ltd, Kezar Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Revive Therapeutics, Moderna, Inc., Parvus Therapeutics, Sigilon Therapeutics, Inc., Orbsen Therapeutics, and others.
• Promising Autoimmune Hepatitis Pipeline Therapies in the various stages of development include Zetomipzomib, HR19042 Capsules, JKB-122, budesonide, prednisone, VAY736, and others.
• November 2023: Kezar Life Sciences Inc. announced a study of Phase 2 clinical trials for zetomipzomib. This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allows patients to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.
• October 2023: Novartis Pharmaceuticals announced a study of Phase 2 & 3 clinical trials for VAY736. This is a randomized, placebo-controlled, double-blind dose range study in autoimmune hepatitis. The study population consists of female and male adult autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care. The diagnosis of autoimmune hepatitis has to fulfill the IAIHG criteria and must be confirmed by liver histology.
• August 2023: Jiangsu HengRui Medicine Co., Ltd announced a study of Phase 2 clinical trials for HR19042 Capsules. This study will evaluate the efficacy and safety of HR19042 capsules for the treatment of autoimmune hepatitis. It will also explore the optimal frequency and dosage of HR19042 capsules administration for the treatment.

 

Request a sample and discover the recent advances in Autoimmune Hepatitis Treatment Drugs @ Autoimmune Hepatitis Pipeline Report

 

In the Autoimmune Hepatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autoimmune Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Autoimmune Hepatitis Overview

Autoimmune hepatitis refers to chronic and progressive inflammation of the liver from an unknown cause. The proposed mechanism for the development of autoimmune hepatitis is thought to be the interplay of genetic predisposition, an environmental trigger, and failure of the native immune system resulting in chronic inflammation of hepatocytes and subsequent fibrosis of the liver.

 

Find out more about Autoimmune Hepatitis Therapeutics Assessment @ Autoimmune Hepatitis Preclinical and Discovery Stage Products

 

Autoimmune Hepatitis Emerging Drugs Profile

• Ianalumab: Novartis
• JKB-122: TaiwanJ Pharmaceuticals

 

Autoimmune Hepatitis Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the Autoimmune Hepatitis therapies. The Autoimmune Hepatitis companies which have their Autoimmune Hepatitis drug candidates in the most advanced stage, i.e. phase II/III include, Novartis.

 

DelveInsight’s Autoimmune Hepatitis pipeline report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Autoimmune Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

Autoimmune Hepatitis Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging Autoimmune Hepatitis Pipeline Therapies @ Autoimmune Hepatitis Clinical Trials Assessment

 

Scope of the Autoimmune Hepatitis Pipeline Report

• Coverage- Global
• Autoimmune Hepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Autoimmune Hepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Autoimmune Hepatitis Companies- Novartis, TaiwanJ Pharmaceuticals Co., Ltd, Kezar Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Revive Therapeutics, Moderna, Inc., Parvus Therapeutics, Sigilon Therapeutics, Inc., Orbsen Therapeutics, and others.
• Autoimmune Hepatitis Pipeline Therapies- Zetomipzomib, HR19042 Capsules, JKB-122, budesonide, prednisone, VAY736, and others.

 

Dive deep into rich insights for new drugs for Autoimmune Hepatitis Treatment, Visit @ Autoimmune Hepatitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Autoimmune Hepatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug name: Company name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II/III)
10. Ianalumab: Novartis
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. JKB-122: TaiwanJ Pharmaceuticals Co., Ltd
14. Drug profiles in the detailed report…..
15. Preclinical Stage Products
16. mRNA-6981: Moderna
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Autoimmune Hepatitis Key Companies
20. Autoimmune Hepatitis Key Products
21. Autoimmune Hepatitis- Unmet Needs
22. Autoimmune Hepatitis- Market Drivers and Barriers
23. Autoimmune Hepatitis- Future Perspectives and Conclusion
24. Autoimmune Hepatitis Analyst Views
25. Autoimmune Hepatitis Key Companies
26. Appendix

 

For further information on the Autoimmune Hepatitis Pipeline therapeutics, reach out to Autoimmune Hepatitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/autoimmune-hepatitis-market